ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / IMTX / earnings
INBX (18) CGEM (32) VOR (46) ODTX (52) ⌘ Pro Terminal →

Immatics N.V. (IMTX) Next Earnings Date & Expected ±12% Move

$7.20 -1.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.17

Immatics N.V. (IMTX) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $1.09B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IMTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IMTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Immatics N.V. (NASDAQ: IMTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $7.20 (-1.50% 1D, market cap $1.09B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IMTX ranks #402 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IMTX compare to INBX and CGEM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMTX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, INBX (Inhibrx Biosciences Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $1.08B) and CGEM (Cullinan Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $994.3M). Among the 5-stock peer group, IMTX leads on earnings multiple (N/A) while INBX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IMTX?
▼

For Immatics N.V. (IMTX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #402 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.17 (-0.46%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.8% Base Target
$13 Bull$7 Base$5 Bear
📬 FREE IMTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMTX)Realized 20D OHLCV Swing Band: ±12%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY IMTX SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (27% of score)

SEC XBRL Trailing 12 Months: 0.8% FCF Margin ($30.6M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
53
Grade C-$7.21-2.2% Next Q
Q2 (-2Q)
50
Grade C-$7.05+1.4% Next Q
Q3 (-1Q)
48
Grade D$7.15+0.7% Next Q
Current
45
Grade D$7.20-6.3% Hist 90D α
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IMTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IMTX currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.22) and Max Pain ($7.56) forces dealer call-delta covering toward $13.03.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMTX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±12% Swing Band

±$0.86 Expected Swing
$6.34 (-12%)Spot $7.20$8.06 (+12%)
MODEL EARNINGS SETUP GAUGE

IMTX Quantitative Pre-Earnings Setup: 45/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (45/100)Model Risk Weight (55/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMTX)

  • ✓Walkthrough of IMTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IMTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.37%▼ DESCENDING CHANNEL
2026-11-02O $7.35H $7.35L $7.20C $7.20VOL 1.18M
RES: $8.46SUP: $6.17SMA50: $8.22SMA200: $9.58
$12.31$10.78$9.24$7.71$6.17RES $8.46SUP $6.17$7.202026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMTX Butterfly Map → + Track IMTX →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IMTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMTX)

Health Care Rank #402 of 1016 ⚔️ INBX vs IMTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMTX vs. INBX, CGEM, VOR, ODTX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Immatics N.V. (IMTX) ranks #402 by composite RQD confidence (45/100, grade D) and #352 by equity capitalization ($1.09B). Within this direct 5-issuer industry benchmark cohort, IMTX leads on earnings valuation at N/A trailing P/E, while INBX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with IMTX at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IMTX ACTIVE
Immatics N.V.
D 45/100 — — — -1.50% $1.09B Benchmark Subject
INBX
Inhibrx Biosciences Inc.
E 18/100 — — -35.0% -2.54% $1.08B /inbx-vs-imtx →
CGEM
Cullinan Therapeutics Inc.
E 32/100 — — -35.0% -2.72% $994.3M /cgem-vs-imtx →
VOR
Vor Biopharma Inc.
D 46/100 — — -35.0% -5.88% $1.24B /vor-vs-imtx →
ODTX
Odyssey Therapeutics Inc.
D+ 52/100 — — — -1.46% $953.0M /odtx-vs-imtx →

2. IMTX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Immatics N.V. (IMTX) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $1.09B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. IMTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Immatics N.V. (NASDAQ: IMTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $7.20 (-1.50% 1D, market cap $1.09B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IMTX ranks #402 in composite RQD confidence.

How does IMTX compare to INBX and CGEM in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMTX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, INBX (Inhibrx Biosciences Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $1.08B) and CGEM (Cullinan Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $994.3M). Among the 5-stock peer group, IMTX leads on earnings multiple (N/A) while INBX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IMTX?

For Immatics N.V. (IMTX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #402 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IMTX trading relative to its 50-day, 200-day, and 52-week technical levels?

IMTX last traded at $7.20 (-1.50% on volume of 1,715,922 shares), positioning the stock -12.41% below its 50-day simple moving average ($8.22) and -24.84% below its 200-day simple moving average ($9.58). Across its 52-week range of $6.65 to $12.41, IMTX sits at the 9.5% percentile with a 14-day RSI of 44.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($6.34 to $8.06).

IMTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is IMTX's next earnings date?

Based on SEC filing cadence, Immatics N.V. (IMTX)'s next quarterly reporting window is estimated around Upcoming Quarter.

How much is IMTX stock expected to move on earnings?

Volatility modeling currently projects a ±12% event move for IMTX, spanning a range between $6.34 and $8.06.

Direct Sub-Reports: IMTX RQD Cockpit IMTX 12M Forecast IMTX Earnings & Move IMTX Dividends & DRIP IMTX Insiders & 13F IMTX Whale Options IMTX Profit Sankey IMTX News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IMTX — Immatics N.V.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:14:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, IMTX scores 45 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars break down as follows:

  • Fundamental Cash Engine: 12 / 20. The rating cites ROIC of 0% and FCF yield of 0%. For a prospective investor, this means the source data shows no measurable return on invested capital and no free-cash yield to anchor valuation.
  • Whale 13F Flow: 3 / 20. This pillar, covering institutional accumulation and options positioning, is the weakest score in the rating. It signals limited evidence of institutional conviction in the source data.
  • Insider Conviction: 9 / 20. The rating references SEC Form 4 and Congressional PTR cluster flow. The low score indicates insider and congressional activity does not offer a supportive signal in the source data.
  • Macro Regime Fit: 8 / 20. The rating cites Beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is modeled to move in line with the broad market, offering no defensive cushion or amplified upside on that basis.
  • Forensic Balance Sheet: 13 / 20. The rating cites Altman Z of 2.5, Piotroski F of 6/9, and Debt/Equity of 0.5. This is the strongest pillar, indicating a relatively more stable balance sheet than the other pillars suggest.

Taken together, the investor implication is that the rating's upside case rests primarily on balance-sheet resilience and any future cash-generation improvement, while the valuation case is weakened by zero ROIC, zero FCF yield, and the weakest institutional-flow score. Valuation tradeoffs are difficult to quantify because P/E, EV/EBITDA, and EPS are not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the catalysts are as follows:

  • A Stock Titan item reports a one-time cell therapy at clinically relevant doses had a 55% confirmed response rate in 20 gynecologic cancer patients. This is flagged as MARKET WIRE (YELLOW).
  • A Stock Traders Daily item is flagged as RISK WATCH (RED) and carries a risk-zone framing, though its body text provides no quantitative detail.
  • Multiple Yahoo Finance and Yahoo! Finance Canada items, a MarketBeat item, and a Google-syndicated item are flagged MARKET WIRE (YELLOW) and largely carry generic "market action" summary language without specific fundamental content.
  • A MarketBeat headline references a consensus target price of $20.60 according to brokerages. This is noted here as a news-headline reference only; the analyst section below addresses it further.

The Butterfly Supply-Chain Graph reports supply_chain as NONE, with no butterfly links and no proprietary signals. No supply-chain catalyst is therefore available in source data.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, sector correlation data, and 2nd-order bottlenecks are not available in source data. A prospective investor should recognize that the absence of mapped dependencies is itself a gap, not evidence of independence from sector trends.

Open Questions

  • What are IMTX's reported revenue, operating income, net income, and free cash flow across recent periods?
  • What is the current trailing and forward earnings valuation, given P/E, EPS, and EV/EBITDA are unavailable?
  • What specific products or therapies generate the company's business, and who are its customers?
  • What is the composition of institutional and insider ownership, and what do recent 13F and Form 4 filings show?
  • How does the gynecologic cancer therapy response data relate to the company's regulatory and commercial timeline?

IMTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Immatics N.V. (IMTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IMTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IMTX Bull vs. Bear Conversation Board — What's Your Call at $7.20?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMTX 🐻 67% BEARISH CONVICTION
1. Pick Your Side on IMTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $6.43 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IMTX (D • RQD 45/100) a Buy at $7.31?

Welcome to the IMTX (Immatics N.V.) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $5.70 (-22.0%)
Spot @ $7.31

Pump the brakes on IMTX — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IMTX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Immatics N.V. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $8.77 (+20.0%)
Spot @ $7.31

IMTX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IMTX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $7.31 (52-wk range $6.65 - $12.41), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%